Drug intelligence / Profile preview

anti-miR-148a

Development stage
Preclinical
Lead developer
University of Virginia
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intraperitoneal
01

Overview

anti-miR-148a is an antisense oligonucleotide designed to inhibit the function of microRNA-148a (miR-148a), an oncogenic microRNA that is frequently overexpressed in glioblastoma (GBM) and other malignancies. In GBM, miR-148a promotes tumor cell proliferation, migration, and invasion while inhibiting apoptosis by targeting the pro-apoptotic molecule BIM and the EGFR negative regulator MIG6. By sequestering miR-148a, anti-miR-148a restores the expression of these target proteins, thereby inducing apoptosis and reducing the self-renewal capacity of GBM stem cells. This therapeutic approach aims to counteract the oncogenic signaling pathways driven by miR-148a, particularly the activation of the EGFR pathway.

Other names
antagomir-148aantagomir148aantagomir 148amiR-148a inhibitormiR148a inhibitormiR 148a inhibitoranti-microRNA-148aanti-microRNA148aanti-microRNA 148a

Beyond the preview

Go deeper on anti-miR-148a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-miR-148a.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call